Figitumumab
Chemical compound / From Wikipedia, the free encyclopedia
Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | IGF-1 receptor |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6462H9948N1736O2020S54 |
Molar mass | 146008.04 g·mol−1 |
![]() ![]() |
Close
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]